OOIR: Observatory of International Research

Papers

(The H4-Index of RMD Open is 34. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial	162
Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey	116
Reactive arthritis after COVID-19 infection	112
Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme	98
Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases	78
Antiphospholipid antibodies in COVID-19: a meta-analysis and systematic review	74
Fibromyalgia: a new facet of the post-COVID-19 syndrome spectrum? Results from a web-based survey	74
Digital rheumatology in the era of COVID-19: results of a national patient and physician survey	73
Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA study	62
Storm, typhoon, cyclone or hurricane in patients with COVID-19? Beware of the same storm that has a different origin	58
Point of view on the vaccination against COVID-19 in patients with autoimmune inflammatory rheumatic diseases	56
Management of Fatigue in Rheumatoid Arthritis	53
Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis	51
Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study	50
Self-protection strategies and health behaviour in patients with inflammatory rheumatic diseases during the COVID-19 pandemic: results and predictors in more than 12 000 patients with inflammatory rhe	48
Current view on the pathogenic role of anti-citrullinated protein antibodies in rheumatoid arthritis	47
Waiting for JAK inhibitor safety data	46
Assessment of impact of the COVID-19 pandemic from the perspective of patients with rheumatic and musculoskeletal diseases in Europe: results from the REUMAVID study (phase 1)	45
Humoral and cellular immune responses on SARS-CoV-2 vaccines in patients with anti-CD20 therapies: a systematic review and meta-analysis of 1342 patients	44
Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzer	43
High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19: first results of ReumaCoV Brasil registry	43
National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of	42
Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who wer	41
Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study	41
Peripheral spondyloarthritis: a neglected entity—state of the art	40

Comparison between idiopathic and VEXAS-relapsing polychondritis: analysis of a French case series of 95 patients	40
Part of pain labelled neuropathic in rheumatic disease might be rather nociplastic	39
Management of lupus nephritis: a systematic literature review informing the 2019 update of the joint EULAR and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA)	38
Pharmacological and non-pharmacological therapeutic strategies in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of diff	37
Seasonal and residential clustering at disease onset of anti-MDA5-associated interstitial lung disease	36
Immune responses to mRNA vaccines against SARS-CoV-2 in patients with immune-mediated inflammatory rheumatic diseases	36
SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry	35
Systemic lupus erythematosus; stroke and myocardial infarction risk: a systematic review and meta-analysis	35
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research	34
DMARD-free remission as novel treatment target in rheumatoid arthritis: A systematic literature review of achievability and sustainability	34